Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy

Abstract Objective. Influenza vaccination is recommended for inflammatory bowel disease (IBD) patients on immunosuppressive therapy. The objective was to evaluate the antibody and cell-mediated immune response to the split and whole virion influenza vaccine in patients with IBD treated with anti-TNF-α and immunosuppressive therapy. Patients and methods.One hundred and fifty-six immunocompromised IBD patients were vaccinated. Fifty-three patients (control group) refused vaccination. Split virion vaccine and whole virion vaccine were used. Serum samples were obtained for pre- and postimmunization antibody titers to influenza vaccine (A/California/7/2009 [H1N1], A/Victoria/361/2011 [H3N2], B/Wisconsin/1/2010–like B/Hubei-Wujiagang/158/2009). Cell-mediated response was evaluated using an interferon (INF)-γ, interleukine (IL)-2 and tumor necrosis factor (TNF)-α ELISA. Results. Postimmunization titers of both influenza subtypes increased significantly after the administration of split virion vaccines compared to the controls and to those who received whole virion vaccine. The antibody titers of Influenza B also increased significantly in patients immunized with split vaccine and treated with anti-TNF-α therapy. After influenza vaccination, the level of serum IL-2 significantly decreased. No serious side effects developed occurred after influenza vaccination, and the influenza-like symptoms did not differ significantly between vaccinated versus control patients. The relapse of the disease was observed in only 10% of the patients and was more common in vaccinated than in control subjects. Conclusion. Split virion vaccines seem to be more effective than whole virion vaccines. Measuring the antibody responses is worthwhile in patients treated with immunosuppressants to determine the efficacy of influenza vaccination.

[1]  D. Frasca,et al.  Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants. , 2013, Journal of Crohn's & colitis.

[2]  E. Garrido,et al.  Efficacy of the vaccination in inflammatory bowel disease. , 2013, World journal of gastroenterology.

[3]  G. Kaplan,et al.  Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease , 2012, Inflammatory bowel diseases.

[4]  S. Faust,et al.  Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. , 2011, Vaccine.

[5]  Zijian Feng,et al.  Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial. , 2010, Vaccine.

[6]  M. Van Ranst,et al.  Vaccinations in patients with immune-mediated inflammatory diseases , 2010, Rheumatology.

[7]  G. Kaplan,et al.  Review: Anti-tumor necrosis factor therapy and influenza: keeping it in perspective , 2010, Therapeutic advances in gastroenterology.

[8]  C. Kallenberg,et al.  Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. , 2009, Arthritis and rheumatism.

[9]  A. Bousvaros,et al.  Immune Response to Influenza Vaccine in Children With Inflammatory Bowel Disease , 2009, The American Journal of Gastroenterology.

[10]  G. Rimmelzwaan,et al.  The effect of anti-tumour necrosis factor α treatment on the antibody response to influenza vaccination , 2007, Annals of the rheumatic diseases.

[11]  Louis J. Cohen,et al.  Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  S. Targan,et al.  Patients with Inflammatory Bowel Disease are at Risk for Vaccine-Preventable Illnesses , 2005, The American Journal of Gastroenterology.

[13]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[14]  R. Klopp,et al.  Specific antibody synthesis in vitro. IV. The correlation of in vitro and in vivo antibody response to influenza vaccine in rhesus monkeys. , 1988, Clinical and experimental immunology.

[15]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[16]  M. Socinski,et al.  Specific antibody synthesis in vitro. III. Correlation of in vivo and in vitro antibody response to influenza immunization in young and old subjects. , 1985, Journal of clinical & laboratory immunology.

[17]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[18]  M. del Río,et al.  Humoral and cell-mediated immune responses to monovalent 2009 influenza A/H1N1 and seasonal trivalent influenza vaccines in high-risk children. , 2012, The Journal of pediatrics.

[19]  H. Tilg,et al.  European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.